Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xvivo Perfusion AB ( (SE:XVIVO) ) just unveiled an update.
XVIVO Perfusion AB has announced the enrollment of the first patient in the US PRESERVE CAP study for its XVIVO Heart Assist Transport device. This study, approved by the FDA, allows continued clinical use of the device while XVIVO prepares its Pre-Market Approval application. The study’s approval by the Centers for Medicare & Medicaid Services ensures cost recovery, supporting both participating centers and patients. This initiative underscores XVIVO’s commitment to providing life-saving technologies and maintaining continuity of care during the evaluation period.
The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
Founded in 1998, XVIVO is a medical technology company focused on extending the life of major organs to aid transplant teams globally. Headquartered in Gothenburg, Sweden, the company is listed on Nasdaq Stockholm and is dedicated to advancing transplantation medicine.
YTD Price Performance: -56.56%
Average Trading Volume: 122,666
Current Market Cap: SEK6.69B
See more insights into XVIVO stock on TipRanks’ Stock Analysis page.